Article
Immunology
Ning Shi, Yangyihua Zhou, Yujun Liu, Ran Zhang, Xingjun Jiang, Caiping Ren, Xiang Gao, Longlong Luo
Summary: In this study, a novel bispecific antibody YG-003D3 targeting PD-1 and LAG-3 was designed, showing strong anti-tumor activity by activating immune cells more effectively. The antibody maintained similar affinity and thermal stability to the parental antibody, and could target multiple cells simultaneously to release the 'brake system of immune checkpoints'. The antibody also exhibited better ability to activate PBMC and alter the proportion of immune cells in the tumor microenvironment.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Pharmacology & Pharmacy
Jii Bum Lee, Sang-Jun Ha, Hye Ryun Kim
Summary: The success of immune checkpoint inhibitors has revolutionized solid tumor treatment, but challenges remain with lack of response and immune related adverse events. Targeting other immune checkpoints associated with tumor microenvironment offers promising options to overcome limitations of ICIs.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Oncology
Christina Bruss, Kerstin Kellner, Veruschka Albert, James A. Hutchinson, Stephan Seitz, Olaf Ortmann, Gero Brockhoff, Anja K. Wege
Summary: Immunotherapies can be used to treat various cancers, but many patients do not respond well and develop resistance, so specific treatment combinations are needed to improve efficacy. Combined anti-PD-1/anti-LAG-3 therapy has been approved for melanoma patients. Humanized tumor mouse models can be used as an important tool for preclinical immunotherapeutic trials.
Review
Oncology
Tian Tian, Zhaoming Li
Summary: Blocking therapy targeting programmed death receptor 1 (PD-1) or programmed death ligand 1 (PD-L1) has revolutionized the treatment of malignant tumors, but patient response rates are low and drug resistance is a major concern. Combining this therapy with Tim-3 blockade may offer a promising approach to overcoming resistance in cancer immunotherapy.
FRONTIERS IN ONCOLOGY
(2021)
Article
Immunology
Wanzun Lin, Yanyan Xu, Jing Gao, Haojiong Zhang, Yun Sun, Xianxin Qiu, Qingting Huang, Lin Kong, Jiade J. Lu
Summary: The study identifies B7-H3 as a novel biomarker for head and neck squamous cell carcinoma (HNSCC), predicting prognosis and response to immunotherapy; high expression of B7-H3 is associated with poor prognosis, immunotherapy resistance, and contributes to an immunosuppressive microenvironment.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Oncology
Chuan Liu, Guangwei Zhang, Kanghui Xiang, Yohan Kim, Roxane R. Lavoie, Fabrice Lucien, Ti Wen
Summary: This review discusses the recent results of clinical trials evaluating the antitumor activity and safety of B7-H3 targeting drugs, as well as the challenges and opportunities arising from their application in cancer treatment. Current gaps in understanding the function and regulation of B7-H3 are pointed out as crucial for unleashing the full clinical utility of B7-H3-based therapies.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Pathology
Yao Sun, Xin Zhou, Elena Lucas, Lili Chen, Huijuan Zhang, Hao Chen, Feng Zhou
Summary: This study found that TIM-3 and B7-H3 are frequently expressed in gastric-type endocervical adenocarcinoma (GEA), and their expression partially overlaps with PD-L1. Moreover, both TIM-3 and B7-H3 are independent negative prognostic markers in GEA.
JOURNAL OF PATHOLOGY CLINICAL RESEARCH
(2023)
Review
Biochemistry & Molecular Biology
Mateusz Kozlowski, Dominika Borzyszkowska, Aneta Cymbaluk-Ploska
Summary: Ovarian cancer has the highest mortality rate among gynecologic malignancies, and current treatment options include surgery and chemotherapy. Immunotherapy is a significant advancement in cancer treatment, and further research on other immune checkpoint inhibitors is needed. Expression of TIM-3 and LAG-3 in the ovarian cancer microenvironment is associated with disease progression and can be utilized for immunotherapy strategies.
Article
Oncology
Tuba N. Gide, Elizabeth C. Paver, Zarwa Yaseen, Nigel Maher, Nurudeen Adegoke, Alexander M. Menzies, Ines Pires da Silva, James S. Wilmott, Georgina V. Long, Richard A. Scolyer
Summary: This study evaluated the association between LAG-3 expression and clinical outcomes in metastatic melanoma patients treated with anti-LAG-3 and anti-PD-1 immunotherapy. The results showed that LAG-3 expression was related to treatment response and tumor-infiltrating lymphocytes, and patients with ≥ 1% LAG-3+ cells had longer progression-free survival.
Article
Pharmacology & Pharmacy
Bing-qi Hu, Jun-feng Huang, Ke Niu, Jing Zhou, Nan-nan Wang, Yu Liu, Wen Chen
Summary: Dihydroartemisinin (DHA), an active metabolite of artemisinin, shows anticancer activities in non-small cell lung cancer (NSCLC) by suppressing tumor growth and inducing CD8+ T lymphocyte infiltration. It inhibits the expression of B7-H3, which is involved in cell proliferation, migration, and apoptosis, rather than PD-L1. These findings suggest that DHA's antitumor effects in NSCLC may be attributed to B7-H3 blockade, indicating a potential combination with anti-PD-L1/PD-1 immunotherapy.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2023)
Article
Cell Biology
Carlo Genova, Roberta Tasso, Alessandra Rosa, Giovanni Rossi, Daniele Reverberi, Vincenzo Fontana, Silvia Marconi, Michela Croce, Maria Giovanna Dal Bello, Chiara Dellepiane, Marco Tagliamento, Maria Chiara Ciferri, Lodovica Zullo, Alessandro Fedeli, Angela Alama, Katia Cortese, Chiara Gentili, Eugenia Cella, Giorgia Anselmi, Marco Mora, Giulia Barletta, Erika Rijavec, Francesco Grossi, Paolo Pronzato, Simona Coco
Summary: The advent of immune checkpoint inhibitors (ICIs) has dramatically changed the treatment of non-small cell lung cancer (NSCLC). However, their efficacy remains limited to a subset of patients. This study evaluated the prognostic role of soluble (s) immune checkpoints and immune checkpoints associated with extracellular vesicles (EVs) in NSCLC patients treated with ICIs. The results showed that high levels of sPD-L1, sB7-H3, and sB7-H4 were associated with different prognoses in advanced NSCLC patients treated with ICIs. The study also suggested potential involvement of EVs in the disease response to ICIs.
Article
Oncology
Ji Liu, Aimaitiaji Kadier, Yadong Guo, Wentao Zhang, Haotian Chen, Zhijin Zhang, Changcheng Guo, Yue Zhang, Meiyu Bao, Jiang Geng, Junfeng Zhang, Shiyu Mao, Xudong Yao
Summary: Through transcriptomic and proteomic analyses, CD276 was identified as a potential target for immunotherapy. In vivo and in vitro experiments confirmed its role in mediating immunotherapeutic effects. CD276 was found to inhibit the enrichment of CD8+ T cells in prostate cancer, suggesting that CD276 inhibitors may be potential targets for immunotherapy.
PROSTATE CANCER AND PROSTATIC DISEASES
(2023)
Review
Chemistry, Analytical
Pei Wang, Longfei Tang, Bohui Zhou, Liangfen Cheng, Robert Chunhua Zhao, Juan Zhang
Summary: Immune checkpoints are a series of molecules that regulate the degree of immune activation, including PD-1/PD-L1, CTLA-4, LAG-3, and others. Immune checkpoint therapy is considered to be a safer and more effective treatment for tumor immunotherapy compared to conventional therapy. The analysis of immune checkpoints is crucial for immunotherapy medication, treatment, and prognosis evaluation.
TRAC-TRENDS IN ANALYTICAL CHEMISTRY
(2022)
Article
Oncology
Jean-Marie Michot, Severine Mouraud, Julien Adam, Julien Lazarovici, Camille Bigenwald, Charlotte Rigaud, Lambros Tselikas, Peggy Dartigues, Alina Danu, Amelie Bigorgne, Veronique Minard, David Ghez, Aurelien Marabelle, Laurence Zitvogel, Vincent Ribrag
Summary: This pilot study found that Hodgkin lymphoma resistant to immunotherapy exhibited depletion of CD8 lymphocytes in the microenvironment and overexpression of the LAG-3 molecule. These findings provide insights into the mechanisms underlying resistance to immunotherapies in patients with Hodgkin lymphoma.
Article
Endocrinology & Metabolism
Xiaoyan Qin, Wenjing Sun, Chong Wang, Mingjiang Li, Xingbo Zhao, Changzhong Li, Hui Zhang
Summary: The study demonstrated that immune checkpoint proteins B7-H2, B7-H3, B7-H4, and PD-L2 are upregulated in adenomyosis tissues, and their expression is downregulated with mifepristone treatment. These findings indicate the involvement of B7 immunomodulatory molecules in the pathophysiology of adenomyosis.
REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGY
(2021)
Review
Medicine, Research & Experimental
Shaho Ghahremani Dehbokri, Nazila Alizadeh, Alireza Isazadeh, Amir Baghbanzadeh, Soheil Abbaspour-Ravasjani, Khalil Hajiasgharzadeh, Behzad Baradaran
Summary: Breast cancer is a prevalent and deadly disease, and its incidence rate is increasing globally. Conventional treatment approaches, such as surgery, radiation therapy, and chemotherapy, often yield unsatisfactory outcomes. Therefore, developing innovative strategies, such as immunotherapy, is crucial for effective breast cancer therapy. The blockade of immune checkpoints, particularly cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), has shown promising results in cancer immunotherapy. The use of anti-CTLA-4 antibodies alone or in combination with other therapeutic agents enhances the tumor-suppressive effects of the immune system and improves cancer prognosis. Immune checkpoint inhibitors hold great potential for breast cancer treatment. This review discusses the role of CTLA-4 and its therapeutic potential in breast cancer therapeutics.
CURRENT MOLECULAR MEDICINE
(2023)
Article
Pharmacology & Pharmacy
Monireh Khordadmehr, Hamed Ezzati, Amirali Shahbazfar, Farinaz Jigari-Asl, Behzad Baradaran, Elham Baghbani, Saeed Noorolyai
Summary: The overexpression of miR-451a can enhance the chemosensitivity of breast cancer cells to carboplatin therapy, which may provide a beneficial strategy for future cancer therapy.
PHARMACEUTICAL SCIENCES
(2023)
Review
Oncology
Samane Abbasi, Milad Asghari Totmaj, Masoumeh Abbasi, Saba Hajazimian, Pouya Goleij, Javad Behroozi, Behrouz Shademan, Alireza Isazadeh, Behzad Baradaran
Summary: Over the last decade, novel therapeutic approaches like CAR-T-cell immunotherapy have transformed the treatment perspective of human malignancies. However, this therapy is associated with side effects and faces challenges in manufacturing, engineering, applications, and toxicities. Further studies are needed to enhance efficacy and minimize adverse events.
Article
Oncology
Elaheh Mohammadali, Reza Safaralizadeh, Arash Poursheikhani, Tooraj Asvadi, Behzad Baradaran, Shahram Teimourian
Summary: This study aimed to evaluate the expression of lncRNA TMPO-AS1 in Iranian patients with gastric cancer (GC). Results showed that TMPO-AS1 was overexpressed in cancerous tissues and could serve as a biomarker to distinguish tumor tissues from normal ones. However, further research is needed to confirm its potential application in the diagnosis, prognosis, and treatment of GC.
INTERNATIONAL JOURNAL OF CANCER MANAGEMENT
(2023)
Article
Oncology
Seyed Samad Hosseini, Paria Nazifi, Mohammad Amini, Felor Zargari, Amir Hossein Yari, Behzad Baradaran, Soltanali Mahboob, Ahad Mokhtarzadeh
Summary: The study showed that crocin decreases cell viability in colorectal cancer cells by upregulating miR-143/145 expression and decreasing KRAS and RREB1 expression dose-dependently. Furthermore, crocin treatment also led to the inactivation of AKT by decreasing its phosphorylation, suggesting a potential inhibitory effect on CRC cell proliferation.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
(2023)
Article
Oncology
Behnaz Mansoori, Shiva Kiani, Alireza Ashrafi Mezajin, Pouyan Zandi, Homadokht Banaie, Davoud Rostamzadeh, William C. Cho, Pascal H. G. Duijf, Behzad Mansoori, Behzad Baradaran
Summary: MiR-143-5p expression is lower in breast cancer tissues compared to normal tissues and low expression is associated with poor prognosis in ER-positive breast cancer patients. Restoration of miR-143-5p suppresses metastasis, reduces cell proliferation, stemness, and promotes apoptosis in ER-positive breast cancer cells through direct targeting of HMGA2. Restoring miR-143-5p could be a promising therapeutic approach for ER-positive breast cancer.
CLINICAL BREAST CANCER
(2023)
Review
Oncology
Zanyar HajiEsmailpoor, Peyman Tabnak, Behzad Baradaran, Fariba Pashazadeh, Leili Aghebati-Maleki
Summary: The purpose of this study was to evaluate the diagnostic performance of computed tomography (CT) scan-based radiomics in predicting lymph node metastasis (LNM) in gastric cancer (GC) patients. The results showed that there were differences in sensitivity, specificity, diagnostic odds ratio (DOR), and area under the curve (AUC) between radiomics models and combined models. Subgroup analysis also found that different CT scan phases, regions of interest (ROIs), and segmentation methods had an impact on diagnostic accuracy. In conclusion, CT scan-based radiomics approach has the potential to predict LNM in GC patients preoperatively as a non-invasive diagnostic tool.
FRONTIERS IN ONCOLOGY
(2023)
Review
Multidisciplinary Sciences
Omid Rahbar Farzam, Niloofar Mehran, Farzaneh Bilan, Ehsan Aghajani, Reza Dabbaghipour, Ghazale Asemani Shahgoli, Behzad Baradaran
Summary: Colorectal cancer, a common malignancy with high mortality, can be effectively treated using imaging-guided photothermal therapy combined with nanotechnology. This approach minimizes side effects and improves treatment outcomes, making it significant for colorectal cancer treatment.
Article
Rheumatology
Roghayeh Tofigh, Mohammadali Hosseinpourfeizi, Reza Safaralizadeh, Sepideh Ghoddusifar, Behzad Baradaran
Summary: This study identifies NEAT1, GAS5, and GAPLINC as promising serological biomarkers in rheumatoid arthritis (RA). The reduced expression of NEAT1 and GAS5 suggests their potential roles as diagnostic and prognostic markers, while the significantly elevated average expression of GAPLINC in RA patients' serum samples indicates its potential as a biomarker candidate for disease stratification. TMEVPG1, on the other hand, displayed unaltered expression levels in RA samples.
CURRENT RHEUMATOLOGY REVIEWS
(2023)
Article
Biology
Rozhin Dabbaghi, Reza Safaralizadeh, Shima Rahmani, Nesa Barpour, Mohammadali Hosseinpourfeizi, Ali Rajabi, Behzad Baradaran
Summary: This study investigates the role of T-bet, IFN-gamma, and MEG3 in the pathogenesis of multiple sclerosis (MS) and their potential as diagnostic and therapeutic targets. The results show that T-bet expression is elevated in treatment-naive relapsing-remitting MS (RRMS) patients compared to healthy individuals. RRMS patients treated with different disease modifying therapies (DMTs) exhibit downregulated T-bet and MEG3 expression levels, with more pronounced effects in females. The correlation between T-bet and MEG3 and between IFN-gamma and T-bet is observed in healthy individuals, while a strong positive correlation is found between MEG3 and IFN-gamma in RRMS patients treated with Glatiramer Acetate (GA). Remarkably, RRMS patients treated with Dimethyl Fumarate (DMF) show a significant positive correlation between T-bet and MEG3. These findings suggest the diagnostic potential of T-bet in RRMS and indicate the need for further exploration of the interplay between MEG3, T-bet, and IFN-gamma in RRMS patients.
BMC RESEARCH NOTES
(2023)
Review
Materials Science, Biomaterials
Zahra Ghahramanipour, Shiva Alipour, Javad Masoumi, Arman Rostamlou, Amirhossein Hatami-Sadr, Javad Ahmadian Heris, Bahar Naseri, Mahdi Jafarlou, Behzad Baradaran
Summary: A functional immune system is crucial for protecting us from infections, tumors, or autoimmune disorders. Micronutrients, particularly vitamins, play important roles in maintaining immune system balance. This review focuses on the roles of vitamins (D, E, A, C) and dendritic cells' subsets in immune processes, including functions, maturation, and cytokine production. Current studies show significant benefits of these vitamins, such as the control of dendritic cells' function and maturation by vitamin E, and the immunoregulatory and anti-inflammatory role of vitamin D. The metabolite of vitamin A, retinoic acid, influences T cell differentiation, and vitamin C has antioxidant effects on dendritic cells. The correlation between vitamin levels and allergic diseases or autoimmunity disorders is also discussed based on previous research.
Review
Biotechnology & Applied Microbiology
Farid Mostafaei, Somayeh Mahdinloo, Hadi Valizadeh, Salar Hemmati, Mahdieh Abdi, Muhammad Sarfraz, Behzad Baradaran, Parvin Zakeri-Milani
Summary: Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer, usually diagnosed in advanced stages. Chemotherapy is commonly used to treat advanced liver cancer but faces challenges that reduce its effectiveness. This review discusses the prevalence, staging, and treatment methods for liver cancer. It also explores recent studies on smart drug- and gene-delivery systems designed specifically for HCC, aiming to improve treatment efficacy.
Review
Oncology
Najibeh Shekari, Dariush Shanehbandi, Tohid Kazemi, Habib Zarredar, Behzad Baradaran, Seyed Amir Jalali
Summary: This article summarizes current evidence on V-domain immunoglobulin suppressor of T cell activation (VISTA), its related ligands, their interactions and effects, as well as preclinical and clinical targeting agents. Investigating VISTA ligands helps understand their functions and roles, and may facilitate the discovery of alternative therapeutic approaches targeting the VISTA pathway.
CANCER CELL INTERNATIONAL
(2023)
Article
Genetics & Heredity
Masoumeh Hajizadeh, Farnaz Hajizadeh, Sevil Ghaffarei, Mohammad Amin Doustvandi, Khadijeh Hajizadeh, Seyyed Mohammad Yaghoubi, Fateme Mohammadnejad, Nadia Allahyarzadeh Khiabani, Pegah Mousavi, Behzad Baradaran
Summary: This review summarizes the role and potential efficacy of miRNAs in promoting and inhibiting cell proliferation and apoptosis in HCC, as well as the role of miRNAs in therapy resistance in HCC.
Article
Medicine, Research & Experimental
Maryam Tohidast, Neda Memari, Mohammad Amini, Seyed Samad Hosseini, Asiyeh Jebelli, Mohammad Amin Doustvandi, Behzad Baradaran, Ahad Mokhtarzadeh
Summary: This study demonstrates that the combination of miR-145 and paclitaxel can inhibit cell proliferation and migration in prostate cancer cells, and enhance chemosensitivity. This combination therapy may be a promising approach for the treatment of prostate cancer.
IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES
(2023)
